跳至主要内容
临床试验/NL-OMON47350
NL-OMON47350已完成3 期

HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET - HD 17 for intermediate stages

Vrije Universiteit Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Histologically proven Hodgkin lymphoma
  • * Newly diagnosed, no previous treatment
  • * Stage I, IIA with RF a-d; stage IIB with RF c, d
  • (a: large mediastinal mass, b: extranodal disease, c: high ESR, d: * 3 lymph node areas)
  • * Age: 18-60 years
  • * Patient had no previous treatment for HL
  • * Normal organ function (except HL-related);
  • * Life expectancy > 3 months.

排除标准

  • * Composite lymphoma
  • * Previous malignancy, prior chemotherapy or radiotherapy
  • * Concurrent diseases which preclude protocol treatment
  • * Pregnancy, lactation
  • * Non-compliance
  • * WHO activity index > 2
  • * Antiepileptic treatment
  • * Concurrent diseases which preclude protocol treatment
  • * Long-term administration of corticosteroids (e.g. for chronic polyarthritis) or antineoplastic drugs (e.g. azathioprine, methotrexate)

研究者

相似试验